- Reply. [Letter]Ophthalmol Retina. 2026 Jul 24. [Online ahead of print]OR
- Publisher Full Text (DOI)
- Viral Retinitis: What We Know and Don't Know. [Editorial]Ophthalmol Retina. 2026 Jul 25. [Online ahead of print]OR
- Publisher Full Text (DOI)
- Re: Kiraly et al: Anatomical and Functional Outcomes after Pars Plana Vitrectomy for Giant Retinal Tear-Related Detachment: The Manchester GRT Study. [Letter]Ophthalmol Retina. 2026 Jul 25. [Online ahead of print]OR
- Publisher Full Text (DOI)
- Re: Hamilton et al: Clinical outcomes of Hydrus microstent implantation for open-angle glaucoma (Ophthalmol Glaucoma. 2026;9:48-61). [Letter]Ophthalmol Glaucoma. 2026 Jul 24. [Online ahead of print]OG
- Publisher Full Text (DOI)
- In Vivo Evidence of the Histopathologic Reappraisal of Posterior Embryotoxon. [Journal Article]Ophthalmol Glaucoma. 2026 Jul 24. [Online ahead of print]OG
- Publisher Full Text (DOI)
- Glucagon-Like Peptide-1 Receptor Agonist and Age-related Macular Degeneration: Adding to the Story. [Editorial]Ophthalmology. 2026 Jul 25. [Online ahead of print]O
- Publisher Full Text (DOI)
- Eye-Preserving Therapies for Early cT3c Retinoblastoma. [Journal Article]Ophthalmology. 2026 Jul 24. [Online ahead of print]O
- CONCLUSIONS: Primary eye-preserving therapies can secure high rates of globe salvage with partial visual function in patients with early cT3c retinoblastoma, without jeopardizing patient survival. However, eyes exhibiting corneal edema or IOP ≥32 mmHg demonstrate markedly inferior salvage outcomes, the treatment strategy for such patients must therefore be cautiously individualized.
- Publisher Full Text (DOI)
- Rare Complications of Selective Laser Trabeculoplasty - Corneal Edema and Thinning in the US Using Insurance Claims Data. [Journal Article]Ophthalmol Glaucoma. 2026 Jul 24. [Online ahead of print]OG
- CONCLUSIONS: Our results suggest that approximately 1 in 1350 adults will develop corneal edema or thinning after SLT. Male and myopic patients undergoing SLT may be at greatest risk for developing post-SLT corneal changes.
- Publisher Full Text (DOI)
- Chorioretinal Atrophy with Posterior Bowing in Alagille Syndrome. [Journal Article]Ophthalmol Retina. 2026 Jul 24. [Online ahead of print]OR
- Publisher Full Text (DOI)
- Foveal Hypoplasia in a Patient with Noonan Syndrome. [Journal Article]Ophthalmol Retina. 2026 Jul 24. [Online ahead of print]OR
- Publisher Full Text (DOI)
- REPLY. [Letter]Ophthalmology. 2026 Jul 24. [Online ahead of print]O
- Publisher Full Text (DOI)
- Anti-VEGF versus Laser Photocoagulation Surgery for Primary Treatment of Retinopathy of Prematurity: Neurodevelopmental Outcomes: A Report by the American Academy of Ophthalmology. [Journal Article]Ophthalmology. 2026 Jul 22. [Online ahead of print]O
- CONCLUSIONS: Although no level I evidence was available, systematically reviewed studies with level II and III evidence showed no evidence that neurodevelopmental outcomes differed among infants who received anti-VEGF compared with LPC for primary treatment of ROP. A limitation to this assessment was that no study was powered for neurodevelopmental outcomes or to detect small differences in neurodevelopmental outcomes.
- Publisher Full Text (DOI)
- Veligrotug: Expanding Treatment Options for Thyroid Eye Disease. [Editorial]Ophthalmology. 2026 Jul 22. [Online ahead of print]O
- Publisher Full Text (DOI)
- Interim Results From a Multicenter Observational Safety Study of Patients Treated With Voretigene Neparvovec-rzyl in the United States. [Journal Article]Ophthalmology. 2026 Jul 22. [Online ahead of print]O
- CONCLUSIONS: This interim analysis supports the long-term safety of VN in a real-world US cohort, consistent with clinical trial results. CRA did not appear to diminish sustained functional and anatomical benefits with a minimum follow-up of nearly 3 years. Ongoing data collection will further clarify the occurrence, impact, and risk factors for CRA while continuing to monitor VN safety in clinical practice.
- Publisher Full Text (DOI)
- Faricimab for High-Need Aflibercept 2 mg Treated Neovascular Age-Related Macular Degeneration. [Journal Article]Ophthalmol Retina. 2026 Jul 22. [Online ahead of print]OR
- CONCLUSIONS: In this first randomized clinical trial comparing faricimab with aflibercept 2 mg in "high-need" aflibercept 2 mg treated nAMD eyes, switching to faricimab was effective in extending treatment intervals in more than a third of eyes.
- Publisher Full Text (DOI)